• In June 2026, Celldex Therapeutics reported long-term Phase 2 results for barzolvolimab in chronic spontaneous urticaria and Phase 1 data for CDX-622, showing rapid, durable angioedema improvement and mast cell depletion, respectively, presented at the European Academy of Allergy and Clinical Immunology meeting in Istanbul.
• The finding that up to 64% of barzolvolimab-treated patients with baseline angioedema remained angioedema-free seven months after dosing raises the prospect of shifting CSU care from symptom management toward possible disease modification.
• We’ll now examine how this potential shift toward disease modification in CSU could shape Celldex’s investment narrative in allergy and inflammation.

The future of work is here. Discover the 32 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

What Is Celldex Therapeutics' Investment Narrative?

To own Celldex today, you have to believe in its mast-cell biology story turning into real, commercial medicines despite heavy losses and minimal current revenue. The June 2026 data for barzolvolimab and CDX-622 strengthen that narrative, reinforcing Celldex’s positioning in allergy and inflammation and helping explain the stock’s recent momentum against an already optimistic DCF view. The barzolvolimab CSU results, with durable, off-treatment angioedema control, arguably make the Q4 2026 Phase 3 readout an even more central near term catalyst, while CDX-622’s early mast cell depletion data broadens the longer term platform angle. At the same time, the business remains unprofitable, is funding an extensive late stage program after a recent US$300.01 million equity raise, and still faces execution and regulatory risk around those same Phase 3 trials.

However, the biggest upside driver is also where the key risk now sits for shareholders. Celldex Therapeutics' shares have been on the rise but are still potentially undervalued. Find out how large the opportunity might be.

Exploring Other Perspectives

Only two Simply Wall St Community fair value views span roughly US$57.53 to US$84.41, yet they already sit well above the current price, even before factoring in the heightened importance of barzolvolimab’s Q4 2026 data for Celldex’s future.

Explore 2 other fair value estimates on Celldex Therapeutics - why the stock might be worth just $57.53!

Decide For Yourself

Disagree with this assessment? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Celldex Therapeutics research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.
• Our free Celldex Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Celldex Therapeutics' overall financial health at a glance.

Curious About Other Options?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• We've uncovered the 9 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Find 44 companies with promising cash flow potential yet trading below their fair value.
• Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.